內地疫情持續升溫 康希諾(06185.HK)曾漲12% 惟開拓(09939.HK)續挫14%
內地疫情持續升溫,A股新冠藥物板塊逆市微升0.3%。然而,本港新冠疫苗股普遍隨大市下跌,尤其是開拓藥物-B(09939.HK)三連跌,今天股價一舉失守50天、20天及10天線(12.3-13.28元),最低見11.32元,現報11.66元,續挫14%。騰盛博藥-B(02137.HK)三連跌,今天高低見7.16元/6.43元,現報6.57元,反覆續跌6.3%。
藥明生物(02269.HK)、國藥(01099.HK)、復星醫藥(02196.HK)、三葉草生物-B(02197.HK)及歌禮-B(01672.HK)跌逾1.5%-3%,後三者沽壓最大,分別低見22元、2.9元及2.82元。
然而,天津市今天起正式啟動接種康希諾(06185.HK)吸入用新冠疫苗工作,康希諾扭兩連吐,股價曾急漲近12%高見119.8元,現報116.3元,回升8.5%;康希諾A(688185.SH)漲7.1%高收255元人民幣。
國家衛健委最新通報,昨天(9日)新增1,133宗本土新冠確診病例,7,691宗本土無症狀感染者;其中廣東仍佔最多,昨天新增500宗本土確診病例,2,507宗本土無症狀感染者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.